CIP
LGND icon

Convergence Investment Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Convergence Investment Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,975
Closed -$681K – 341
2018
Q3 		$681K Sell
3,975
-7,498
-65% -$1.13M 0.14% 181
2018
Q2 		$1.48M Sell
11,473
-5,942
-34% -$663K 0.21% 143
2018
Q1 		$1.79M Sell
17,415
-6,168
-26% -$610K 0.23% 150
2017
Q4 		$2.02M Buy
23,583
+1,939
+9% +$168K 0.27% 128
2017
Q3 		$1.84M Buy
+21,644
New +$1.71M 0.26% 146

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Convergence Investment Partners's LGND Position: Q4 2018 in Review

Convergence Investment Partners sold out of Ligand Pharmaceuticals (LGND) in Q4 2018, closing a stake of 3,975 shares — an estimated $681K sold.

Convergence Investment Partners first reported a position in LGND in Q3 2017 and held it in 5 quarters. The position peaked at $2.02M in Q4 2017. 362 funds tracked by Wall St. Rank hold LGND as of Q4 2018.

  • Convergence Investment Partners reported no remaining Ligand Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Convergence Investment Partners sold 3,975 Ligand Pharmaceuticals shares in Q4 2018, an estimated $681K.
  • Convergence Investment Partners first reported a position in Ligand Pharmaceuticals in Q3 2017 and held it in 5 quarters.
  • Convergence Investment Partners's Ligand Pharmaceuticals position peaked at $2.02M in Q4 2017.
  • 362 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2018.

Based on Convergence Investment Partners's 13F filing for Q4 2018, filed 13 Feb 2019.